-
1
-
-
84897012482
-
BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: A systematic review and meta-analysis
-
Chen D, Huang JF, Liu K, et al. BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis. PLoS One 2014; 9:e90607.
-
(2014)
PLoS One
, vol.9
, pp. e90607
-
-
Chen, D.1
Huang, J.F.2
Liu, K.3
-
2
-
-
84904736732
-
BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer
-
Yaeger R, Cercek A, Chou JF, et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer 2014; 120:2316-2324.
-
(2014)
Cancer
, vol.120
, pp. 2316-2324
-
-
Yaeger, R.1
Cercek, A.2
Chou, J.F.3
-
3
-
-
84919466731
-
The BRAF mutation is associated with the prognosis in colorectal cancer
-
Ahn TS, Jeong D, Son MW, et al. The BRAF mutation is associated with the prognosis in colorectal cancer. J Cancer Res Clin Oncol 2014; 140:1863-1871.
-
(2014)
J Cancer Res Clin Oncol
, vol.140
, pp. 1863-1871
-
-
Ahn, T.S.1
Jeong, D.2
Son, M.W.3
-
4
-
-
84878581633
-
KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells
-
Lewandowska MA, Jozwicki W, Zurawski B. KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells. Mol Diagn Ther 2013; 17:193-203.
-
(2013)
Mol Diagn Ther
, vol.17
, pp. 193-203
-
-
Lewandowska, M.A.1
Jozwicki, W.2
Zurawski, B.3
-
5
-
-
84999986042
-
The MAPK pathway across different malignancies: A new perspective
-
Burotto M, Chiou VL, Lee JM, Kohn EC. The MAPK pathway across different malignancies: a new perspective. Cancer 2014; 120:3446-3456.
-
(2014)
Cancer
, vol.120
, pp. 3446-3456
-
-
Burotto, M.1
Chiou, V.L.2
Lee, J.M.3
Kohn, E.C.4
-
6
-
-
84898005888
-
ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer
-
Ye Q, Cai W, Zheng Y, et al. ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer. Oncogene 2014; 33:1828-1839.
-
(2014)
Oncogene
, vol.33
, pp. 1828-1839
-
-
Ye, Q.1
Cai, W.2
Zheng, Y.3
-
7
-
-
63149194964
-
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
-
Pratilas CA, Taylor BS, Ye Q, et al. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci USA 2009; 106:4519-4524.
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, pp. 4519-4524
-
-
Pratilas, C.A.1
Taylor, B.S.2
Ye, Q.3
-
8
-
-
84898462986
-
Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer
-
Roper J, Sinnamon MJ, Coffee EM, et al. Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer. Cancer Lett 2014; 347:204-211.
-
(2014)
Cancer Lett
, vol.347
, pp. 204-211
-
-
Roper, J.1
Sinnamon, M.J.2
Coffee, E.M.3
-
9
-
-
84874762857
-
Molecular biological diagnostics of KRAS and BRAF mutations in patients with colorectal cancer - Laboratory experience
-
Robesova B, Bajerova M, Vasikova A, et al. Molecular biological diagnostics of KRAS and BRAF mutations in patients with colorectal cancer - laboratory experience. Klin Onkol 2013; 26:25-30.
-
(2013)
Klin Onkol
, vol.26
, pp. 25-30
-
-
Robesova, B.1
Bajerova, M.2
Vasikova, A.3
-
10
-
-
84898901842
-
Clinical meaning of BRAF mutation in Korean patients with advanced colorectal cancer
-
Kim B, Park SJ, Cheon JH, et al. Clinical meaning of BRAF mutation in Korean patients with advanced colorectal cancer. World J Gastroenterol 2014; 20:4370-4376.
-
(2014)
World J Gastroenterol
, vol.20
, pp. 4370-4376
-
-
Kim, B.1
Park, S.J.2
Cheon, J.H.3
-
11
-
-
84888883391
-
Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer
-
Marchoudi N, Amrani Hassani Joutei H, Jouali F, et al. Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer. Pathol Biol (Paris) 2013; 61:273-276.
-
(2013)
Pathol Biol (Paris)
, vol.61
, pp. 273-276
-
-
Marchoudi, N.1
Amrani Hassani Joutei, H.2
Jouali, F.3
-
12
-
-
84908292763
-
FDA approval summary: Vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation
-
Kim G, McKee AE, Ning YM, et al. FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation. Clin Cancer Res 2014; 20:4994-5000.
-
(2014)
Clin Cancer Res
, vol.20
, pp. 4994-5000
-
-
Kim, G.1
McKee, A.E.2
Ning, Y.M.3
-
13
-
-
84883237132
-
Dabrafenib: First global approval
-
Ballantyne AD, Garnock-Jones KP. Dabrafenib: first global approval. Drugs 2013; 73:1367-1376.
-
(2013)
Drugs
, vol.73
, pp. 1367-1376
-
-
Ballantyne, A.D.1
Garnock-Jones, K.P.2
-
14
-
-
84880780573
-
Trametinib: First global approval
-
Wright CJ, McCormack PL. Trametinib: first global approval. Drugs 2013; 73:1245-1254.
-
(2013)
Drugs
, vol.73
, pp. 1245-1254
-
-
Wright, C.J.1
McCormack, P.L.2
-
15
-
-
84903201668
-
BRAF mutations: Signaling, epidemiology, and clinical experience in multiple malignancies
-
Hall RD, Kudchadkar RR. BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies. Cancer Contr 2014; 21:221-230.
-
(2014)
Cancer Contr
, vol.21
, pp. 221-230
-
-
Hall, R.D.1
Kudchadkar, R.R.2
-
16
-
-
84896721004
-
EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: A prospective follow-up study
-
Schweiger T, Hegedus B, Nikolowsky C, et al. EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study. Ann Surg Oncol 2014; 21:946-954.
-
(2014)
Ann Surg Oncol
, vol.21
, pp. 946-954
-
-
Schweiger, T.1
Hegedus, B.2
Nikolowsky, C.3
-
17
-
-
84889962719
-
The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer
-
Huang CW, Tsai HL, Chen YT, et al. The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer. BMC Cancer 2013; 13:599.
-
(2013)
BMC Cancer
, vol.13
, pp. 599
-
-
Huang, C.W.1
Tsai, H.L.2
Chen, Y.T.3
-
18
-
-
84896044667
-
Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: A meta-analysis of randomized studies
-
Cui D, Cao D, Yang Y, et al. Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies. Mol Biol Rep 2014; 41:1291-1298.
-
(2014)
Mol Biol Rep
, vol.41
, pp. 1291-1298
-
-
Cui, D.1
Cao, D.2
Yang, Y.3
-
19
-
-
84896689696
-
KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells
-
Nakadate Y, Kodera Y, Kitamura Y, et al. KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells. Int J Cancer 2014; 134:2146-2155.
-
(2014)
Int J Cancer
, vol.134
, pp. 2146-2155
-
-
Nakadate, Y.1
Kodera, Y.2
Kitamura, Y.3
-
20
-
-
84919662543
-
BRAF V600E mutation as a predictive factor of anti-EGFR monoclonal antibodies therapeutic effects in metastatic colorectal cancer: A meta-analysis
-
Wang Q, Hu WG, Song QB, Wei J. BRAF V600E mutation as a predictive factor of anti-EGFR monoclonal antibodies therapeutic effects in metastatic colorectal cancer: a meta-analysis. Chi Med Sci J 2014; 29:197-203.
-
(2014)
Chi Med Sci J
, vol.29
, pp. 197-203
-
-
Wang, Q.1
Hu, W.G.2
Song, Q.B.3
Wei, J.4
-
21
-
-
84929141867
-
Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: A meta-analysis of randomized, controlled trials
-
Sorich MJ, Wiese MD, Rowland A, et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol ESMO 2015; 26:13-21.
-
(2015)
Ann Oncol ESMO
, vol.26
, pp. 13-21
-
-
Sorich, M.J.1
Wiese, M.D.2
Rowland, A.3
-
22
-
-
84928487327
-
KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: A meta-analysis
-
Li W, Shi Q, Wang W, et al. KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis. Colorectal Dis 2014; 16:O370-O378.
-
(2014)
Colorectal Dis
, vol.16
, pp. O370-O378
-
-
Li, W.1
Shi, Q.2
Wang, W.3
-
23
-
-
77956030786
-
Inhibition of mutated, activated BRAF in metastatic melanoma
-
Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. NEJM 2010; 363:809-819.
-
(2010)
NEJM
, vol.363
, pp. 809-819
-
-
Flaherty, K.T.1
Puzanov, I.2
Kim, K.B.3
-
24
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. NEJM 2011; 364:2507-2516.
-
(2011)
NEJM
, vol.364
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
-
25
-
-
78649723255
-
PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors
-
Chicago, IL; 2010
-
Kopetz S Desai J, Chan E, et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. ASCO AnnualMeeting 2010; Chicago, IL; 2010.
-
(2010)
ASCO AnnualMeeting
-
-
Kopetz Desai S, J.1
Chan, E.2
-
26
-
-
84901631862
-
Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAFmutant colorectal cancer cells
-
Hirschi B, Gallmeier E, Ziesch A, et al. Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAFmutant colorectal cancer cells. Mol Cancer 2014; 13:122.
-
(2014)
Mol Cancer
, vol.13
, pp. 122
-
-
Hirschi, B.1
Gallmeier, E.2
Ziesch, A.3
-
27
-
-
84873360893
-
Resistance to BRAF inhibition in BRAFmutant colon cancer can be overcome with PI3K inhibition or demethylating agents
-
Mao M, Tian F, Mariadason JM, et al. Resistance to BRAF inhibition in BRAFmutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 2013; 19:657-667.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 657-667
-
-
Mao, M.1
Tian, F.2
Mariadason, J.M.3
-
28
-
-
84878066430
-
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer
-
Coffee EM, Faber AC, Roper J, et al. Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer. Clin Cancer Res 2013; 19:2688-2698.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 2688-2698
-
-
Coffee, E.M.1
Faber, A.C.2
Roper, J.3
-
29
-
-
84863230465
-
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
-
Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483:100-103.
-
(2012)
Nature
, vol.483
, pp. 100-103
-
-
Prahallad, A.1
Sun, C.2
Huang, S.3
-
30
-
-
84861863158
-
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
-
Corcoran RB, Ebi H, Turke AB, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012; 2:227-235.
-
(2012)
Cancer Discov
, vol.2
, pp. 227-235
-
-
Corcoran, R.B.1
Ebi, H.2
Turke, A.B.3
-
31
-
-
84881223991
-
Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer
-
Spreafico A, Tentler JJ, Pitts TM, et al. Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. Clin Cancer Res 2013; 19:4149-4162.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 4149-4162
-
-
Spreafico, A.1
Tentler, J.J.2
Pitts, T.M.3
-
32
-
-
84897407253
-
Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib
-
Cheng H, Chang Y, Zhang L, et al. Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib. J Med Chem 2014; 57:2692-2703.
-
(2014)
J Med Chem
, vol.57
, pp. 2692-2703
-
-
Cheng, H.1
Chang, Y.2
Zhang, L.3
-
33
-
-
84863012433
-
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer
-
Yang H, Higgins B, Kolinsky K, et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res 2012; 72:779-789.
-
(2012)
Cancer Res
, vol.72
, pp. 779-789
-
-
Yang, H.1
Higgins, B.2
Kolinsky, K.3
-
34
-
-
79952001479
-
Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer
-
Galal KM, Khaled Z, Mourad AM. Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer. Indian J Cancer 2011; 48:47-54.
-
(2011)
Indian J Cancer
, vol.48
, pp. 47-54
-
-
Galal, K.M.1
Khaled, Z.2
Mourad, A.M.3
-
35
-
-
84892402986
-
Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAF (V600E)-mutant metastatic colorectal carcinoma
-
Connolly K, Brungs D, Szeto E, Epstein RJ. Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAF (V600E)-mutant metastatic colorectal carcinoma. Curr Oncol 2014; 21:e151-e154.
-
(2014)
Curr Oncol
, vol.21
, pp. e151-e154
-
-
Connolly, K.1
Brungs, D.2
Szeto, E.3
Epstein, R.J.4
-
36
-
-
84903828105
-
Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: A case report
-
Capalbo C, Marchetti P, Coppa A, et al. Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: a case report. Cancer Biol Ther 2014; 15:826-831.
-
(2014)
Cancer Biol Ther
, vol.15
, pp. 826-831
-
-
Capalbo, C.1
Marchetti, P.2
Coppa, A.3
-
37
-
-
84880100858
-
Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer
-
Al-Marrawi MY, Saroya BS, Brennan MC, et al. Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. Cancer Biol Ther 2013; 14:703-710.
-
(2013)
Cancer Biol Ther
, vol.14
, pp. 703-710
-
-
Al-Marrawi, M.Y.1
Saroya, B.S.2
Brennan, M.C.3
-
38
-
-
78651418282
-
Mutant BRAF melanomas: Dependence and resistance
-
Poulikakos PI, Rosen N. Mutant BRAF melanomas: dependence and resistance. Cancer Cell 2011; 19:11-15.
-
(2011)
Cancer Cell
, vol.19
, pp. 11-15
-
-
Poulikakos, P.I.1
Rosen, N.2
|